Biomarker Testing in Advanced Colon Cancer: Why It's Still Lagging

We speak with one of the authors of a recent study examining why overall biomarker testing rates remain poor for metastatic colorectal cancer.

Although genomic testing is recognized in national oncology guidelines as key to determining the right therapy for metastatic colorectal cancer (mCRC), overall biomarker testing rates remain poor. On this episode of Managed Care Cast, we speak with one of the authors of a recent study about this issue published in JCO Precision Oncology. Stuart Goldberg, MD, a hematologist oncologist at the John Theurer Cancer Center at Hackensack University Medical Center, discusses real-world testing of biomarkers in mCRC, uncovered through mining electronic health records.

Goldberg is also the hospital’s first chief of the Division of Outcomes and Value Research, and the episode also discusses the relationship between value-based medicine and precision medicine and the promise of delivering improved outcomes at lower costs by avoiding ineffective therapies through the use of specialized testing and diagnostics.

Listen above or through one of these podcast services:






Gutierrez ME, Price KS, Lanman RB, et al. Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer [published online December 6, 2019]. JCO Precis Oncol. doi: 10.1200/PO.19.00274.

Related Videos
Related Content
© 2023 MJH Life Sciences
All rights reserved.